Aprilbio Co., Ltd. 397030

KRX · South Korea · Health Technology

KRW 21,300.00+1,100.00 (+5.45%)

Market closed· Oct 1, 2026, 6:30 AM UTC· KRW · Data may be delayed

Prices may be delayed and are for informational purposes only - not investment advice.

Aprilbio Co., Ltd. 397030

KRX · South Korea · Health Technology

KRW 21,300.00+1,100.00 (+5.45%)

Market closed· Oct 1, 2026, 6:30 AM UTC· KRW · Data may be delayed

Prices may be delayed and are for informational purposes only - not investment advice.

-62.23% · 6MFull-screen chart

Open KRW 19,980.00High KRW 21,450.00Low KRW 19,620.00Close KRW 21,300.00Volume 322.75K

Oct 1, 2026

Charts by TradingView Lightweight Charts

Key statistics

Previous close: KRW 20,200.00
Day range: KRW 19,620.00 – KRW 21,450.00
52-week range: KRW 16,450.00 – KRW 76,700.00
Volume: 322.75K
Market cap: KRW 556.69B
Avg. volume (1Y): 559.96K

Performance

1 week

+13.90%

1 month

+18.20%

3 months

-34.86%

6 months

-56.80%

Year to date

-59.81%

1 year

-31.07%

Total return, dividends included.

Company profile

Sector: Health Technology
Industry: Biotechnology
Country: South Korea
Exchange: KRX
Shares outstanding: 27.56M
Employees: 27
ISIN: KR7397030008
Beta: 0.91

Technical view

Below averages

Where the price sits against its 50- and 200-day moving averages.

Valuation & analysis

Makkler Fair Value, financial health score, analyst view, peers and MakklerAI.

News

Yahoo FinanceFeb 11, 2026

Evommune rockets on eczema data; AstraZeneca advances GLP-1 pill

Shares of Evommune nearly doubled on data suggesting it has a potential threat to Dupixent. Elsewhere, a closely watched narcolepsy drug got an FDA decision date and investors scrutinized Upstream’s asthma results.

Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.